XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3
STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Aug. 31, 2024
Aug. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (741,170) $ (539,509)
Adjustments to reconcile net loss to net cash used by operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. 471,125 363,226
Changes in operating assets and liabilities    
Prepaids 600 600
Accounts payable 68,293 (12,570)
Accrued liabilities (6,476) 3,182
NET CASH USED BY OPERATING ACTIVITIES (207,628) (185,071)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 207,534 185,534
NET CASH PROVIDED BY FINANCING ACTIVITIES 207,534 185,534
NET INCREASE (DECREASE) IN CASH (94) 463
CASH AT BEGINNING OF PERIOD 1,310 934
CASH AT END OF PERIOD $ 1,216 $ 1,397